A Phase Ib Clinical Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Metastatic Pancreatic Adenocarcinoma

Trial Profile

A Phase Ib Clinical Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Metastatic Pancreatic Adenocarcinoma

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 05 Jun 2018

At a glance

  • Drugs Napabucasin (Primary) ; Fluorouracil; Folinic acid; Gemcitabine; Irinotecan; Oxaliplatin; Paclitaxel
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Adverse reactions
  • Sponsors Boston Biomedical
  • Most Recent Events

    • 05 Jun 2018 Results (n=59) presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
    • 01 Jun 2018 Results presented in a Boston Biomedical media release.
    • 17 May 2018 According to the Sumitomo Dainippon Pharma media release, data from this study will be presented at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top